Physician profile
Diane Ditusa
NPI 1225283278
$3,664.58
in general payments reported to CMS, 2019-2025
36 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $474 · 2021: $547 · 2022: $641 · 2023: $1,161 · 2024: $65.89 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872 · Travel and Lodging: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.93 |
| Travel and Lodging | $628.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $777.34 | 2023 | Da Vinci Surgical System |
| Hologic Sales and Service, LLC | $390.81 | 2019-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Acessa Provu System, Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $366.67 | 2019-2025 | |
| Abbvie INC. | $302.38 | 2019-2022 | |
| Exeltis, USA INC. | $207.20 | 2019-2025 | Slynd |
| Medtronic, INC. | $179.50 | 2022-2023 | Interstim |
| Daiichi Sankyo INC. | $160.31 | 2020-2023 | Injectafer |
| Organon LLC | $148.68 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $138.16 | 2020-2024 | Phexxi |
| Sumitomo Pharma America, INC. | $121.01 | 2023-2025 | Myfembree |
| Therapeuticsmd, INC. | $90.22 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $85.89 | 2021-2023 | |
| Smith+Nephew, INC. | $66.00 | 2019 | |
| Radius Health, INC. | $65.51 | 2019-2023 | |
| Allergan, INC. | $64.47 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $58.30 | 2019 | |
| Amgen INC. | $53.79 | 2019-2023 | Prolia, Evenity |
| Avion Pharmaceuticals | $44.61 | 2019-2021 | |
| Astellas Pharma US INC | $31.99 | 2021-2023 | Myrbetriq |
| Pfizer INC. | $29.45 | 2022-2023 | |
| Agile Therapeutics, INC. | $28.18 | 2021-2022 | |
| Coopersurgical, INC. | $26.22 | 2019-2023 | Paragard T 380a |
| Alydia Health | $25.81 | 2021 | |
| Myovant Sciences INC. | $25.77 | 2021-2022 | |
| Roche Diagnostics Corporation | $22.90 | 2021 | |
| Lupin INC. | $15.47 | 2019 | |
| Aspira Women'S Health INC | $15.26 | 2023 | Ova1 |
| Mylan Pharmaceuticals INC. | $15.00 | 2021 | |
| Merck Sharp & Dohme LLC | $14.17 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $14.01 | 2025 | Exparel |
| Biohaven Pharmaceutical Holding Company LTD. | $13.91 | 2022 | |
| Medicem INC. | $13.82 | 2020 | |
| Scynexis, INC. | $13.75 | 2021 | |
| Mimedx Group, INC. | $13.45 | 2024 | |
| Amag Pharmaceuticals, INC. | $13.43 | 2019 | |
| Dysis Medical, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Ditusa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.